A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease. 1996

H L Sham, and C Zhao, and K D Stewart, and D A Betebenner, and S Lin, and C H Park, and X P Kong, and W Rosenbrook, and T Herrin, and D Madigan, and S Vasavanonda, and N Lyons, and A Molla, and A Saldivar, and K C Marsh, and E McDonald, and N E Wideburg, and J F Denissen, and T Robins, and D J Kempf, and J J Plattner, and D W Norbeck
Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064-3500.

The design, synthesis, and molecular modeling studies of a novel series of azacyclic ureas, which are inhibitors of human immunodeficiency virus type 1 (HIV-1) protease that incorporate different ligands for the S1', S2, and S2' substrate-binding sites of HIV-1 protease are described. The synthesis of this series is highly flexible in the sense that the P1', P2, and P2' residues of the inhibitors can be changed independently. Molecular modeling studies on the phenyl ring of the P2 and P2' ligand suggested incorporation of hydrogen-bonding donor/acceptor groups at the 3' and 4-positions of the phenyl ring should increase binding potency. This led to the discovery of compound 7f (A-98881), which possesses high potency in the HIV-1 protease inhibition assay and the in vitro MT-4 cell culture assay (Ki = approximately 5 pM and EC50 = 0.002 microM). This compares well with the symmetrical cyclic urea 1 pioneered at DuPont Merck.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016333 HIV Protease Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. HIV Proteinase,HTLV-III Protease,p16 pol gene product, HIV,p16 protease, HIV,HIV p16 protease,HTLV III Protease,Protease, HIV,Protease, HTLV-III
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

H L Sham, and C Zhao, and K D Stewart, and D A Betebenner, and S Lin, and C H Park, and X P Kong, and W Rosenbrook, and T Herrin, and D Madigan, and S Vasavanonda, and N Lyons, and A Molla, and A Saldivar, and K C Marsh, and E McDonald, and N E Wideburg, and J F Denissen, and T Robins, and D J Kempf, and J J Plattner, and D W Norbeck
April 2008, Antimicrobial agents and chemotherapy,
H L Sham, and C Zhao, and K D Stewart, and D A Betebenner, and S Lin, and C H Park, and X P Kong, and W Rosenbrook, and T Herrin, and D Madigan, and S Vasavanonda, and N Lyons, and A Molla, and A Saldivar, and K C Marsh, and E McDonald, and N E Wideburg, and J F Denissen, and T Robins, and D J Kempf, and J J Plattner, and D W Norbeck
May 2000, Clinical therapeutics,
H L Sham, and C Zhao, and K D Stewart, and D A Betebenner, and S Lin, and C H Park, and X P Kong, and W Rosenbrook, and T Herrin, and D Madigan, and S Vasavanonda, and N Lyons, and A Molla, and A Saldivar, and K C Marsh, and E McDonald, and N E Wideburg, and J F Denissen, and T Robins, and D J Kempf, and J J Plattner, and D W Norbeck
April 2002, Antiviral research,
H L Sham, and C Zhao, and K D Stewart, and D A Betebenner, and S Lin, and C H Park, and X P Kong, and W Rosenbrook, and T Herrin, and D Madigan, and S Vasavanonda, and N Lyons, and A Molla, and A Saldivar, and K C Marsh, and E McDonald, and N E Wideburg, and J F Denissen, and T Robins, and D J Kempf, and J J Plattner, and D W Norbeck
October 2000, Archives of biochemistry and biophysics,
H L Sham, and C Zhao, and K D Stewart, and D A Betebenner, and S Lin, and C H Park, and X P Kong, and W Rosenbrook, and T Herrin, and D Madigan, and S Vasavanonda, and N Lyons, and A Molla, and A Saldivar, and K C Marsh, and E McDonald, and N E Wideburg, and J F Denissen, and T Robins, and D J Kempf, and J J Plattner, and D W Norbeck
September 2000, Virology,
H L Sham, and C Zhao, and K D Stewart, and D A Betebenner, and S Lin, and C H Park, and X P Kong, and W Rosenbrook, and T Herrin, and D Madigan, and S Vasavanonda, and N Lyons, and A Molla, and A Saldivar, and K C Marsh, and E McDonald, and N E Wideburg, and J F Denissen, and T Robins, and D J Kempf, and J J Plattner, and D W Norbeck
June 2005, Antimicrobial agents and chemotherapy,
H L Sham, and C Zhao, and K D Stewart, and D A Betebenner, and S Lin, and C H Park, and X P Kong, and W Rosenbrook, and T Herrin, and D Madigan, and S Vasavanonda, and N Lyons, and A Molla, and A Saldivar, and K C Marsh, and E McDonald, and N E Wideburg, and J F Denissen, and T Robins, and D J Kempf, and J J Plattner, and D W Norbeck
May 1997, Archives of internal medicine,
H L Sham, and C Zhao, and K D Stewart, and D A Betebenner, and S Lin, and C H Park, and X P Kong, and W Rosenbrook, and T Herrin, and D Madigan, and S Vasavanonda, and N Lyons, and A Molla, and A Saldivar, and K C Marsh, and E McDonald, and N E Wideburg, and J F Denissen, and T Robins, and D J Kempf, and J J Plattner, and D W Norbeck
April 1994, Proceedings of the National Academy of Sciences of the United States of America,
H L Sham, and C Zhao, and K D Stewart, and D A Betebenner, and S Lin, and C H Park, and X P Kong, and W Rosenbrook, and T Herrin, and D Madigan, and S Vasavanonda, and N Lyons, and A Molla, and A Saldivar, and K C Marsh, and E McDonald, and N E Wideburg, and J F Denissen, and T Robins, and D J Kempf, and J J Plattner, and D W Norbeck
March 2002, The Pediatric infectious disease journal,
H L Sham, and C Zhao, and K D Stewart, and D A Betebenner, and S Lin, and C H Park, and X P Kong, and W Rosenbrook, and T Herrin, and D Madigan, and S Vasavanonda, and N Lyons, and A Molla, and A Saldivar, and K C Marsh, and E McDonald, and N E Wideburg, and J F Denissen, and T Robins, and D J Kempf, and J J Plattner, and D W Norbeck
January 1995, Journal of cellular biochemistry. Supplement,
Copied contents to your clipboard!